Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | TAS2R46 | P59540 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TAS2R31 | P59538 | 2/20 | 0.35 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937997 | 1.00 | LMNA (0.58) | LMNATSHRTAS2R46ALDH1A1NPC1 | |
| SCHEMBL2878253 | 1.00 | LMNA (0.58) | LMNATSHRTAS2R46ALDH1A1NPC1 | |
| Valine SCHEMBL15477725 | 0.83 | LMNA (0.46) | LMNATSHRALDH1A1NPC1RAB9A | |
| SCHEMBL937318 | 0.82 | LMNA (0.60) | LMNATSHRTAS2R46ALDH1A1NPC1 | |
| SCHEMBL1037667 | 0.82 | LMNA (0.60) | LMNATSHRTAS2R46ALDH1A1NPC1 | |
| SCHEMBL937050 | 0.82 | LMNA (0.60) | LMNATSHRTAS2R46ALDH1A1NPC1 | |
| SCHEMBL12909964 | 0.82 | LMNA (0.66) | LMNATSHRTAS2R46ALDH1A1NPC1 | |
| SCHEMBL1783157 | 0.82 | LMNA (0.66) | LMNATSHRTAS2R46ALDH1A1NPC1 | |
| SCHEMBL15450107 | 0.82 | LMNA (0.66) | LMNATSHRTAS2R46ALDH1A1NPC1 | |
| SCHEMBL23128326 | 0.80 | LMNA (0.58) | LMNATSHRTAS2R46ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-3219713-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3219713-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| WO-2012087596-A1 | COMBINATIONS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087596-A1 | COMBINATIONS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20110178129-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178129-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178129-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011088345-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088345-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2011011303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456414-B2 | Methods for treating HCV | HAVCR2, HCCS, LIPC | LMNA 4253/4885TSHR 4167/4885TAS2R46 4471/4885 |
| US-20170189439-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | LMNA 4253/4885TSHR 4167/4885TAS2R46 4471/4885 |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | LMNA 1554/4885TSHR 4286/4885TAS2R46 2835/4885 |
| US-20110178129-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | LMNA 1554/4885TSHR 4286/4885TAS2R46 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.